SEATTLE and SOUTH SAN FRANCISCO, Calif., Nov. 13, 2014 (GLOBE NEWSWIRE) -- Immune Design Corp. (Nasdaq:IMDZ), a clinical-stage immunotherapy company, today announced that Carlos Paya, M.D., Ph.D., President and Chief Executive Officer of Immune Design, will present at the Jefferies 2014 Global Healthcare Conference in London on November 19, 2014 at 11:20 a.m. GMT/3:20 a.m. PST. A live audio webcast and archive of the presentation will be available on the company website at http://ir.immunedesign.com/events.cfm.
About Immune Design
Immune Design is a clinical-stage immunotherapy company employing next-generation in vivo approaches to enable the body's immune system to fight disease. The company's technologies are engineered to activate the immune system's natural ability to create and/or expand antigen-specific cytotoxic T cells, while enhancing other immune effectors, to fight cancer and other chronic diseases. Immune Design's three on-going immuno-oncology clinical programs are the product of its two synergistic discovery platforms: ZVexTM and GLAASTM. Immune Design has offices in Seattle and South San Francisco. For more information, visit www.immunedesign.com.